Loading
A phase 3 trial testing BNT324 in prostate cancer, now recruiting.
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07365995, led by BioNTech SE with BioNTech (Shanghai) Pharmaceuticals and DualityBio, and recruiting on the registry. Official title: A Phase III, Randomised, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer. Planned enrolment is 736 participants (estimated). The study started in 2026-04-22 and primary completion is expected in 2031-02. No results have been posted on ClinicalTrials.gov.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.